

Bong-Soo Cha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7440398/publications.pdf>

Version: 2024-02-01

110
papers

3,455
citations

186209

28
h-index

161767

54
g-index

115
all docs

115
docs citations

115
times ranked

5543
citing authors

#	ARTICLE	IF	CITATIONS
1	Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008–2011). <i>Journal of Hepatology</i> , 2015, 63, 486-493.	1.8	264
2	SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. <i>Nature Communications</i> , 2020, 11, 2127.	5.8	263
3	Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008–2011). <i>Hepatology</i> , 2016, 63, 776-786.	3.6	261
4	Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 2654-2660.	4.3	245
5	Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition. <i>Autophagy</i> , 2017, 13, 1767-1781.	4.3	152
6	The Effectiveness of Intermittent Fasting to Reduce Body Mass Index and Glucose Metabolism: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1645.	1.0	112
7	Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis. <i>Diabetes and Metabolism Journal</i> , 2019, 43, 31.	1.8	109
8	Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies. <i>Scientific Reports</i> , 2016, 6, 24013.	1.6	89
9	Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. <i>Journal of Hepatology</i> , 2018, 68, 764-772.	1.8	86
10	Metformin Restores Parkin-Mediated Mitophagy, Suppressed by Cytosolic p53. <i>International Journal of Molecular Sciences</i> , 2016, 17, 122.	1.8	73
11	Glycated albumin is a useful glycation index for monitoring fluctuating and poorly controlled type 2 diabetic patients. <i>Acta Diabetologica</i> , 2011, 48, 167-172.	1.2	71
12	Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. <i>American Journal of Gastroenterology</i> , 2020, 115, 584-595.	0.2	68
13	Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis. <i>Free Radical Biology and Medicine</i> , 2016, 99, 520-532.	1.3	62
14	Association between dietary acid load and the risk of cardiovascular disease: nationwide surveys (KNHANES 2008–2011). <i>Cardiovascular Diabetology</i> , 2016, 15, 122.	2.7	62
15	Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPAR γ agonists. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 289, E151-E159.	1.8	59
16	Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial. <i>Journal of Diabetes Investigation</i> , 2016, 7, 366-373.	1.1	56
17	Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. <i>Metabolism: Clinical and Experimental</i> , 2017, 66, 23-31.	1.5	55
18	Sarcopenia is associated with albuminuria independently of hypertension and diabetes: KNHANES 2008–2011. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1531-1540.	1.5	46

#	ARTICLE	IF	CITATIONS
19	Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 382.	1.8	46
20	Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 259.	1.0	44
21	Lithospermic acid B protects beta-cells from cytokine-induced apoptosis by alleviating apoptotic pathways and activating anti-apoptotic pathways of Nrf2/HO-1 and Sirt1. <i>Toxicology and Applied Pharmacology</i> , 2011, 252, 47-54.	1.3	42
22	Urinary N-acetyl-β-D-glucosaminidase, an early marker of diabetic kidney disease, might reflect glucose excursion in patients with type 2 diabetes. <i>Medicine (United States)</i> , 2016, 95, e4114.	0.4	41
23	Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via interorgan crosstalk. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 801-811.	2.2	40
24	Dietary Monounsaturated Fatty Acids but not Saturated Fatty Acids Preserve the Insulin Signaling Pathway via IRS-1/PI3K in Rat Skeletal Muscle. <i>Lipids</i> , 2010, 45, 1109-1116.	0.7	37
25	Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment. <i>Diabetes and Metabolism Journal</i> , 2019, 43, 127.	1.8	37
26	Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 290-299.	1.4	37
27	Serum PTHrP Predicts Weight Loss in Cancer Patients Independent of Hypercalcemia, Inflammation, and Tumor Burden. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1207-1214.	1.8	34
28	Risk of Incident Dementia According to Metabolic Health and Obesity Status in Late Life: A Population-Based Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2942-2952.	1.8	32
29	Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2408-2415.	2.2	30
30	Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study). <i>BMC Medicine</i> , 2022, 20, 93.	2.3	30
31	Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 267.	1.8	28
32	Anatomic fat depots and cardiovascular risk: a focus on the leg fat using nationwide surveys (KNHANES 2008-2011). <i>Cardiovascular Diabetology</i> , 2017, 16, 54.	2.7	26
33	Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus. <i>Frontiers in Endocrinology</i> , 2018, 9, 412.	1.5	26
34	The renal tubular damage marker urinary N-acetyl-β-d-glucosaminidase may be more closely associated with early detection of atherosclerosis than the glomerular damage marker albuminuria in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2017, 16, 16.	2.7	25
35	Blood Pressure Levels and Risks of Dementia: a Nationwide Study of 4.5 Million People. <i>Hypertension</i> , 2022, 79, 218-229.	1.3	24
36	Is albuminuria an indicator of myocardial dysfunction in diabetic patients without overt heart disease? A study with Doppler strain and strain rate imaging. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 448-452.	1.5	23

#	ARTICLE	IF	CITATIONS
37	Relationship Between Circulating Netrin-1 Concentration, Impaired Fasting Glucose, and Newly Diagnosed Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2018, 9, 691.	1.5	23
38	Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 81.	2.7	23
39	Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle. <i>Life Sciences</i> , 2009, 84, 688-695.	2.0	22
40	Association Between Heme Oxygenase-1 Promoter Polymorphisms and the Development of Albuminuria in Type 2 Diabetes. <i>Medicine (United States)</i> , 2015, 94, e1825.	0.4	22
41	Free Fatty Acid Metabolism in Human Skeletal Muscle Is Regulated by PPAR γ and RXR Agonists. <i>Annals of the New York Academy of Sciences</i> , 2002, 967, 66-70.	1.8	21
42	Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2020, 46, 362-369.	1.4	21
43	Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 921-932.	1.8	21
44	Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 326-336.	1.8	21
45	Hyperleptinemia as a Robust Risk Factor of Coronary Artery Disease and Metabolic Syndrome in Type 2 Diabetic Patients. <i>Endocrine Journal</i> , 2008, 55, 1085-1092.	0.7	20
46	Increased expression of ATP-binding cassette transporter A1 (ABCA1) as a possible mechanism for the protective effect of cilostazol against hepatic steatosis. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1444-1453.	1.5	19
47	Waist-to-calf circumference ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1082-1091.	1.4	19
48	Severe Hypoglycemia Increases Dementia Risk and Related Mortality: A Nationwide, Population-based Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1976-e1986.	1.8	19
49	Glycated albumin and the risk of micro- and macrovascular complications in subjects with Type 1 Diabetes. <i>Cardiovascular Diabetology</i> , 2015, 14, 53.	2.7	18
50	Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis. <i>Endocrinology and Metabolism</i> , 2018, 33, 219.	1.3	18
51	Comparison and Validation of 10 Equations Including a Novel Method for Estimation of LDL-cholesterol in a 168,212 Asian Population. <i>Medicine (United States)</i> , 2016, 95, e3230.	0.4	17
52	Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors. <i>Diabetes and Metabolism Journal</i> , 2019, 43, 158.	1.8	17
53	Causal Relationship of Non-alcoholic Fatty Liver Disease with Obesity and Insulin Resistance. <i>Journal of Korean Diabetes</i> , 2014, 15, 76.	0.1	16
54	Current Management of Type 2 Diabetes Mellitus in Primary Care Clinics in Korea. <i>Endocrinology and Metabolism</i> , 2019, 34, 282.	1.3	16

#	ARTICLE	IF	CITATIONS
55	The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment. <i>European Journal of Endocrinology</i> , 2007, 157, 167-174.	1.9	15
56	Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 165-172.	1.5	14
57	Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial. <i>Diabetes and Metabolism Journal</i> , 2017, 41, 135.	1.8	14
58	Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 786-797.	1.4	14
59	Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis. <i>Medicine (United States)</i> , 2016, 95, e4543.	0.4	13
60	The Relation between Birth Weight and Insulin Resistance in Korean Adolescents. <i>Yonsei Medical Journal</i> , 2006, 47, 85.	0.9	13
61	Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus. <i>Endocrinology and Metabolism</i> , 2015, 30, 84.	1.3	12
62	Impact of diabetes mellitus and chronic liver disease on the incidence of dementia and all-cause mortality among patients with dementia. <i>Medicine (United States)</i> , 2017, 96, e8753.	0.4	12
63	Gamma glutamyltransferase and risk of dementia in prediabetes and diabetes. <i>Scientific Reports</i> , 2020, 10, 6800.	1.6	12
64	A Case of Multiple Endocrine Neoplasia Type 1 Combined with Papillary Thyroid Carcinoma. <i>Yonsei Medical Journal</i> , 2008, 49, 503.	0.9	11
65	Spontaneous ketonuria and risk of incident diabetes: a 12-year prospective study. <i>Diabetologia</i> , 2019, 62, 779-788.	2.9	11
66	Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1041-1051.	2.2	11
67	The level of 2-h post-challenge glucose is an independent risk factor of carotid intima-media thickness progression in Korean type 2 diabetic patients. <i>Journal of Diabetes and Its Complications</i> , 2007, 21, 7-12.	1.2	9
68	Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes. <i>Endocrinology and Metabolism</i> , 2017, 32, 274.	1.3	9
69	Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β -Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis. <i>Diabetes Therapy</i> , 2019, 10, 149-158.	1.2	9
70	Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipopoptosis via modulating hepatic dipeptidyl peptidase-4 expression. <i>Scientific Reports</i> , 2020, 10, 19429.	1.6	9
71	Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes. <i>Medicine (United States)</i> , 2020, 99, e21038.	0.4	9
72	Uric Acid Variability as a Predictive Marker of Newly Developed Cardiovascular Events in Type 2 Diabetes. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 775753.	1.1	9

#	ARTICLE	IF	CITATIONS
73	Differential association of ezetimibe-simvastatin combination with major adverse cardiovascular events in patients with or without diabetes: a retrospective propensity score-matched cohort study. <i>Scientific Reports</i> , 2018, 8, 11925.	1.6	8
74	Efficacy and safety of lobe-glitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1869-1873.	2.2	8
75	Short Term Isocaloric Ketogenic Diet Modulates NLRP3 Inflammasome Via B-hydroxybutyrate and Fibroblast Growth Factor 21. <i>Frontiers in Immunology</i> , 2022, 13, 843520.	2.2	8
76	Use of a Diabetes Self-Assessment Score to Predict Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Medicine (United States)</i> , 2015, 94, e1103.	0.4	7
77	Glycated Albumin Levels in Patients with Type 2 Diabetes Increase Relative to HbA1c with Time. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	7
78	The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1c in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study. <i>Diabetes Therapy</i> , 2017, 8, 601-609.	1.2	7
79	Predictive Factors for Efficacy of AST-120 Treatment in Diabetic Nephropathy: a Prospective Single-Arm, Open-Label, Multi-Center Study. <i>Journal of Korean Medical Science</i> , 2019, 34, e117.	1.1	7
80	Pre-sarcopenia is associated with renal hyperfiltration independent of obesity or insulin resistance. <i>Medicine (United States)</i> , 2017, 96, e7165.	0.4	6
81	Clinical efficacy of the novel thiazolidinedione lobe-glitazone in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2018, 44, 452-455.	1.4	6
82	Elevated N-acetyl-β-D-glucosaminidase, a urinary tubular damage marker, is a significant predictor of carotid artery atherosclerosis in type 1 diabetes, independent of albuminuria: A cross-sectional study. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 777-783.	1.2	6
83	Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 103-111.	2.2	6
84	Association Between Serum Bilirubin and the Progression of Carotid Atherosclerosis in Type 2 Diabetes. <i>Journal of Lipid and Atherosclerosis</i> , 2020, 9, 195.	1.1	6
85	Proteinuria Is Associated with Carotid Artery Atherosclerosis in Non-Albuminuric Type 2 Diabetes: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 136.	1.0	6
86	Analysis of Severe Hypoglycemia Among Adults With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. <i>JAMA Network Open</i> , 2022, 5, e220262.	2.8	6
87	Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 241-247.	0.6	6
88	Morning Spot Urine Glucose-to-Creatinine Ratios Predict Overnight Urinary Glucose Excretion in Patients With Type 2 Diabetes. <i>Annals of Laboratory Medicine</i> , 2017, 37, 9-17.	1.2	5
89	Effects of Serum Albumin, Calcium Levels, Cancer Stage and Performance Status on Weight Loss in Parathyroid Hormone-Related Peptide Positive or Negative Patients with Cancer. <i>Endocrinology and Metabolism</i> , 2018, 33, 97.	1.3	5
90	Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 405-414.	1.1	5

#	ARTICLE	IF	CITATIONS
91	<p></p>Effect of Switching from Linagliptin to Tenzeligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus</p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 4113-4121.	1.1	5
92	Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2022, 46, 104-116.	1.8	5
93	Cost-effectiveness analysis of low density lipoprotein cholesterol-lowering therapy in hypertensive patients with type 2 diabetes in Korea: single-pill regimen (amlodipine/atorvastatin) versus double-pill regimen (amlodipine+atorvastatin). Epidemiology and Health, 2015, 37, e2015010.	0.8	5
94	Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial. International Journal of Clinical Practice, 2017, 71, e12987.	0.8	4
95	Glucometabolic characteristics and higher vascular complication risk in Korean patients with type 2 diabetes with non-albumin proteinuria. Journal of Diabetes and Its Complications, 2019, 33, 585-591.	1.2	4
96	Comparison of Renal Effects of Ezetimibe+Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis. Journal of Clinical Medicine, 2020, 9, 798.	1.0	4
97	Characteristics of Type 2 Diabetes in Terms of Insulin Resistance in Korea. Yonsei Medical Journal, 2005, 46, 484.	0.9	3
98	Comparison of the Efficacy and Safety of Glimpiride/Metformin Fixed Combination Versus Free Combination in Patients with Type 2 Diabetes: Multicenter, Randomized, Controlled Trial. The Journal of Korean Diabetes Association, 2006, 30, 466.	0.1	3
99	Central obesity is an independent risk factor for microalbuminuria in both the general Korean women and nondiabetic nonhypertensive subpopulation: Association of microalbuminuria and metabolic syndrome from the Korea National Health and Nutrition Examination Survey 2011-2012. Clinica Chimica Acta, 2015, 448, 74-79.	0.5	3
100	Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus. Transplantation Proceedings, 2019, 51, 3444-3448.	0.3	3
101	Diabetes self-assessment score and the development of diabetes. Medicine (United States), 2017, 96, e7067.	0.4	2
102	Proteinuria as a significant predictive factor for the progression of carotid artery atherosclerosis in non-albuminuric type 2 diabetes. Diabetes Research and Clinical Practice, 2021, 181, 109082.	1.1	2
103	Paroxetine-induced Hypoglycemia in Type 2 Diabetic Patient. The Ewha Medical Journal, 2016, 39, 14.	0.1	1
104	Characteristics Predictive for a Successful Switch from Insulin Analogue Therapy to Oral Hypoglycemic Agents in Patients with Type 2 Diabetes. Yonsei Medical Journal, 2016, 57, 1395.	0.9	1
105	Effects of Combination Therapy of Statin and Thiazolidinedione on Vascular Inflammation. Korean Circulation Journal, 2018, 48, 602.	0.7	1
106	The long term effects of rosiglitazone on serum lipid concentration and body weight. The Journal of Korean Diabetes Association, 2006, 30, 17.	0.1	0
107	Fellows' perception of fellowship training and overarching issues. Journal of the Korean Medical Association, 2016, 59, 969.	0.1	0
108	Reply to "The association between sarcopenia and non-alcoholic fatty liver disease: Potential pitfalls in non-invasive prediction models". Journal of Hepatology, 2016, 64, 520-521.	1.8	0

#	ARTICLE	IF	CITATIONS
109	Cover Image, Volume 21, Issue 4. Diabetes, Obesity and Metabolism, 2019, 21, i.	2.2	0
110	Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes. Yonsei Medical Journal, 2022, 63, 539.	0.9	0